OPP002_Predictive_Responder_Analytics 📄 Overview An advanced AI platform that leverages a combination of pre-treatment patient data (genomics, metabolomics, gut microbiome profile, lifestyle factors) and early-phase treatment responses (e.g., initial weight change, symptom severity via app) to predict individual patient response to specific GLP-1 agonists (or combination therapies) and forecast the likelihood and severity of common side effects. This SaMD tool would aid clinicians in personalized drug selection, dosing, and proactive management strategies to improve efficacy and reduce adverse events. Key technologies: 👤 Target users: 👍 Benefits Improved patient selection and stratification for GLP-1 therapy • Reduced trial-and-error in medication selection and dosage • Lower rates of non-response and early treatment discontinuation • Proactive management of side effects, enhancing patient tolerability • Cost savings by avoiding ineffective treatments for non-responders • Acceleration of R&D for next-generation metabolic therapies Use bullets or new lines. 👎 Challenges Acquiring sufficient high-quality, diverse multi-omics and clinical data for model training • Ensuring the generalizability and interpretability of complex AI models • Regulatory hurdles for a predictive SaMD with diagnostic/prognostic claims (likely Class III) • Ethical considerations around patient stratification and potential access inequities • Data privacy and security for highly sensitive genomic and health data. 📋 Regulatory & Validation Highly likely Class III SaMD due to influencing diagnosis/treatment selection, requiring pre-market approval (PMA) equivalent or robust clinical trial data. • Strong emphasis on algorithm validation, bias testing, and real-world performance monitoring. • Comprehensive data governance for sensitive patient data.